Navigation Links
Archemix in Medical News

Alexandria Real Estate Equities Provides Update

...ical represented approximately 13% and were dominated by high-quality, leading-edge companies with blue chip venture investors, including Ambrx, Inc., archemix Corp., Fate Therapeutics, Inc., Juvaris BioTherapeutics, Inc. and TolerRx, Inc.; and the remainder of approximately 7% was comprised of traditional ...

Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

...icology studies for a number of biologic compounds, including monoclonal antibody immunoconjugates and nucleic acids at Millennium Pharmaceuticals and archemix Corp. Dr. Green will lead Taligen's development project teams for the company's two most advanced clinical candidates, TT30 and TA106, acros...

Isis Reports Financial Results and Highlights for Fiscal year 2007

...ction with Roche. * Isis licensed technology to archemix for aptamer drug applications in exchange for...s and royalties on aptamer drugs developed by archemix that incorporate Isis' proprietary chemistries or ...sis received the first milestone payment from archemix for the advancement of Archemix' aptamer drug into...
Archemix in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...velop drugs that incorporate Isis' technology resulting in financial benefits as these assets mature. Isis earned milestone payments from archemix and Alnylam because each company advanced drugs that incorporate Isis' technology. Isis co-exclusively licensed its single-stranded RNA interfe...

Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172

...llaborative Effort In August 2006, Nuvelo expanded its collaboration with archemix to develop and commercialize aptamers that have a short-acting anticoagulant effect. Under the agreement, archemix is responsible for discovery of short-acting aptamers for use in medical pr...

Archemix Announces Completion of Phase 1 Trial of ARC1779

... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - archemix Corp., a biotechnology company focused on discover...n as thrombotic thrombocytopenic purpura, or TTP. archemix plans to present a complete data set from this Pha...esized rather than biologically expressed. About archemix ...
Archemix in Biological Technology

Biotech Avoids Fall Out From Tough Quarter for Capital Markets

...Biotech IPOs on hold The prevailing tough economic environment also took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...

Biotech Drops Amid Tough Markets in February

...otech IPOs remain on hold The prevailing tough economic environment took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused o...
Other Tags
(Date:7/13/2014)... 13, 2014 Max International ... Mullin, will be the featured guest at its Charity ... Puerto Rico. Attendees will learn about Max’s health ... two exhibition basketball games and perform in a 3 ... of health- and energy-boosting supplements , has recently announced ...
(Date:7/13/2014)... July 13, 2014 A decreased ability to ... impairment and Alzheimer,s disease, while examinations of the ... protein associated with Alzheimer,s, in the brain, according ... today at the Alzheimer,s Association International Conference 2014 ... the studies, the decreased ability to identify odors ...
(Date:7/13/2014)... July 13, 2014 ECS ... commented, “As a parent of a special needs child, ... in the Seattle community for contemporary special education resources ... important alternative to students and families in the Seattle ... and environment for special education. We welcome the opportunity ...
(Date:7/13/2014)... iFitDress.com, one of the most popular suppliers of wedding ... new selection of beautiful evening dresses to ... for these evening gowns. Now, everybody can enjoy a ... of graceful gowns in its online store. Most of ... and many other countries. They are highly appreciated by ...
(Date:7/12/2014)... July 12, 2014 The Passenger Information ... in 2013 to $20,341.36 million by 2019, at an ... and 2019. , The public transport infrastructure in North ... also available in almost every corner of the region. ... interest of public transport service providers are driving the ...
Breaking Medicine News(10 mins):Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4
(Date:7/11/2014)... mesenchymal stem cells can stimulate neurogenesis in the brain ... (AD) and improve tissue and function injury under the ... the therapeutic effect of adipose-derived stem cells (ADSCs) transplantation ... oxidative injury and neurogenesis in the brain of AD ... Life Sciences, Tsinghua University, China transplanted ADSCs into the ...
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... software and services, previously announced on June 26, 2014 ... cash dividend of $1.75 per share, or approximately $40 ... of July 10, 2014 and a payment date of ... NASDAQ that it had set an ex-dividend date for ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
Other Contents